agilon health, inc. Stock-Based Compensation
agilon health, inc. (AGL) reported Stock-Based Compensation of $30.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- agilon health, inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $23.83M, a 54.94% increase year-over-year.
- agilon health, inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $6.25M, a 62.59% decline year-over-year.
- agilon health, inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $9.52M, a 317.18% increase year-over-year.
- agilon health, inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $7.50M, a 43.45% decline year-over-year.
- agilon health, inc. share-based payment arrangement, noncash expense for fiscal 2025 was $49.12M, a 3.04% decline from fiscal 2024.
- agilon health, inc. share-based payment arrangement, noncash expense for fiscal 2024 was $50.66M, a 27.11% decline from fiscal 2023.
- agilon health, inc. share-based payment arrangement, noncash expense for fiscal 2023 was $69.50M, a 144.86% increase from fiscal 2022.
- agilon health, inc. share-based payment arrangement, noncash expense for fiscal 2022 was $28.38M, a 90.29% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $30.09M 10-Q · filed 2026-08-05 | $39.61M derived: sum of 3 quarters · filed 2026-08-05 | $47.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $6.25M 10-Q · filed 2026-05-06 | $15.78M derived: sum of 2 quarters · filed 2026-05-06 | $23.27M derived: sum of 3 quarters · filed 2026-05-06 | $38.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $17.02M derived: sum of 2 quarters · filed 2026-02-25 | $32.40M derived: sum of 3 quarters · filed 2026-08-05 | $49.12M 10-K · filed 2026-02-25 |
| 2025-09-30 | $7.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $22.88M derived: sum of 2 quarters · filed 2026-08-05 | $39.60M 10-Q · filed 2025-11-04 | $41.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $15.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $32.10M 10-Q · filed 2026-08-05 | $34.38M derived: sum of 3 quarters · filed 2026-08-05 | $47.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $16.72M 10-Q · filed 2026-05-06 | $19.00M derived: sum of 2 quarters · filed 2026-05-06 | $32.26M derived: sum of 3 quarters · filed 2026-05-06 | $50.47M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $15.54M derived: sum of 2 quarters · filed 2026-02-25 | $33.75M derived: sum of 3 quarters · filed 2026-02-25 | $50.66M 10-K · filed 2026-02-25 |
| 2024-09-30 | $13.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $31.47M derived: sum of 2 quarters · filed 2025-11-04 | $48.38M 10-Q · filed 2025-11-04 | $63.89M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $18.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $35.12M 10-Q · filed 2025-08-04 | $50.63M derived: sum of 3 quarters · filed 2026-02-25 | $71.37M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $16.91M 10-Q · filed 2025-05-06 | $32.42M derived: sum of 2 quarters · filed 2026-02-25 | $53.16M derived: sum of 3 quarters · filed 2026-02-25 | $72.73M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $15.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $36.25M derived: sum of 2 quarters · filed 2026-02-25 | $55.82M derived: sum of 3 quarters · filed 2026-02-25 | $69.50M 10-K · filed 2026-02-25 |
| 2023-09-30 | $20.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $40.31M derived: sum of 2 quarters · filed 2024-11-07 | $53.98M 10-Q · filed 2024-11-07 | $63.93M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $19.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $33.24M 10-Q · filed 2024-08-06 | $43.20M derived: sum of 3 quarters · filed 2025-02-25 | $51.10M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $13.67M 10-Q · filed 2024-05-07 | $23.62M derived: sum of 2 quarters · filed 2025-02-25 | $31.53M derived: sum of 3 quarters · filed 2025-02-25 | $38.08M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $9.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $17.86M derived: sum of 2 quarters · filed 2025-02-25 | $24.41M derived: sum of 3 quarters · filed 2025-02-25 | $28.38M 10-K · filed 2025-02-25 |
| 2022-09-30 | $7.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $14.46M derived: sum of 2 quarters · filed 2023-11-02 | $18.43M 10-Q · filed 2023-11-02 | $22.84M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $6.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $10.52M 10-Q · filed 2023-08-03 | $14.94M derived: sum of 3 quarters · filed 2024-02-27 | $26.90M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $3.97M 10-Q · filed 2023-05-09 | $8.38M derived: sum of 2 quarters · filed 2024-02-27 | $20.34M derived: sum of 3 quarters · filed 2024-02-27 | $294.89M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $16.37M derived: sum of 2 quarters · filed 2024-02-27 | $290.92M derived: sum of 3 quarters · filed 2024-02-27 | $292.39M 10-K · filed 2024-02-27 |
| 2021-09-30 | $11.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $286.51M derived: sum of 2 quarters · filed 2022-11-03 | $287.98M 10-Q · filed 2022-11-03 | $289.75M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $274.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $276.02M 10-Q · filed 2022-08-04 | $277.79M derived: sum of 3 quarters · filed 2023-03-01 | $279.41M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $1.47M 10-Q · filed 2022-05-05 | $3.24M derived: sum of 2 quarters · filed 2023-03-01 | $4.86M derived: sum of 3 quarters · filed 2023-03-01 | $7.09M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $3.39M derived: sum of 2 quarters · filed 2023-03-01 | $5.62M derived: sum of 3 quarters · filed 2023-03-01 | $6.69M 10-K · filed 2023-03-01 |
| 2020-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $3.85M derived: sum of 2 quarters · filed 2021-10-28 | $4.92M 10-Q · filed 2021-10-28 | |
| 2020-06-30 | $2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $3.30M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $1.07M 10-Q · filed 2021-05-26 | |||
| 2019-12-31 | $5.22M 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |